<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Sibi JM</submitter><pubmed_abstract>&lt;h4>Aim&lt;/h4>Metabolic syndrome (MS) refers to a group of co-morbidities which include central obesity, hypertension, hyperglycemia and dyslipidemia. Previously, we reported that childhood lymphatic filariasis (LF) confers significant protection against type-1 and type-2 forms of diabetes, by means of immunomodulation. In the present study, we studied the effect of LF on endocrine dysfunction in MS and Non-MS patients in baseline and after 10 years of follow-up.&lt;h4>Methods&lt;/h4>We quantified the serum levels of pancreatic hormones (insulin and glucagon), incretins (Ghrelin, GIP and GLP-1) and adipokines (leptin, adiponectin, adipsin, visfatin, PAI-1 and resistin) by multiplex bead array system.&lt;h4>Results&lt;/h4>MS (both LF- and LF+) subjects had increased insulin levels compared to NMS (both L</pubmed_abstract><journal>Frontiers in endocrinology</journal><pagination>1011942</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9723321</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Modulatory effect of filarial infection on the systemic hormone levels in subjects with metabolic syndrome (DM-LF5).</pubmed_title><pmcid>PMC9723321</pmcid><pubmed_authors>Babu S</pubmed_authors><pubmed_authors>Sibi JM</pubmed_authors><pubmed_authors>Aravindhan V</pubmed_authors><pubmed_authors>Deepa M</pubmed_authors><pubmed_authors>Mohan V</pubmed_authors></additional><is_claimable>false</is_claimable><name>Modulatory effect of filarial infection on the systemic hormone levels in subjects with metabolic syndrome (DM-LF5).</name><description>&lt;h4>Aim&lt;/h4>Metabolic syndrome (MS) refers to a group of co-morbidities which include central obesity, hypertension, hyperglycemia and dyslipidemia. Previously, we reported that childhood lymphatic filariasis (LF) confers significant protection against type-1 and type-2 forms of diabetes, by means of immunomodulation. In the present study, we studied the effect of LF on endocrine dysfunction in MS and Non-MS patients in baseline and after 10 years of follow-up.&lt;h4>Methods&lt;/h4>We quantified the serum levels of pancreatic hormones (insulin and glucagon), incretins (Ghrelin, GIP and GLP-1) and adipokines (leptin, adiponectin, adipsin, visfatin, PAI-1 and resistin) by multiplex bead array system.&lt;h4>Results&lt;/h4>MS (both LF- and LF+) subjects had increased insulin levels compared to NMS (both L</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-06-01T02:33:12.931Z</modification><creation>2024-11-15T06:20:31.046Z</creation></dates><accession>S-EPMC9723321</accession><cross_references><pubmed>36482987</pubmed><doi>10.3389/fendo.2022.1011942</doi></cross_references></HashMap>